We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Talos Energy
TALO
$2.38B
| $6.99M | 0.04% |
+824,826
| New | +$6.61M |
|
502
Ocular Therapeutix
OCUL
$1.89B
| $6.97M | 0.04% |
750,950
| – | – |
|
503
Spyre Therapeutics
SYRE
$9.11B
| $6.96M | 0.04% |
465,152
+344
| +0.1% | +$5.09K |
|
504
Apollo Global Management
APO
$76.8B
| $6.93M | 0.04% |
48,829
+11,065
| +29% | +$1.47M |
|
505
Hilton Worldwide
HLT
$70.2B
| $6.85M | 0.04% |
25,712
+5,385
| +26% | +$1.28M |
|
506
Moderna
MRNA
$22.8B
| $6.81M | 0.04% |
246,973
+2,641
| +1% | +$69.5K |
|
507
Kura Sushi USA
KRUS
$588M
| $6.79M | 0.04% |
+78,856
| New | +$5.17M |
|
508
Marriott International
MAR
$90B
| $6.72M | 0.04% |
24,591
+5,259
| +27% | +$1.32M |
|
509
AutoZone
AZO
$49.4B
| $6.72M | 0.04% |
1,809
+391
| +28% | +$1.44M |
|
510
Xencor
XNCR
$1.48B
| $6.63M | 0.04% |
843,296
| – | – |
|
511
Entegris
ENTG
$22B
| $6.61M | 0.03% |
+82,009
| New | +$6.23M |
|
512
Chemours
CC
$2.7B
| $6.6M | 0.03% |
+576,315
| New | +$6.49M |
|
513
Vaxcyte
PCVX
$7.9B
| $6.5M | 0.03% |
200,078
-911,699
| -82% | -$29.9M |
|
514
Hayward Holdings
HAYW
$3.41B
| $6.41M | 0.03% |
+464,643
| New | +$6.26M |
|
|
TECX
515
Tectonic Therapeutic
TECX
$550M
| $6.39M | 0.03% |
321,637
+19,422
| +6% | +$394K |
|
516
Kenvue
KVUE
$37.5B
| $6.37M | 0.03% |
304,205
-469,661
| -61% | -$10.7M |
|
517
Emerson Electric
EMR
$89B
| $6.36M | 0.03% |
+47,717
| New | +$5.47M |
|
518
Nektar Therapeutics
NKTR
$2.46B
| $6.36M | 0.03% |
246,145
+20
| +0% | +$225 |
|
519
Monolithic Power Systems
MPWR
$65.6B
| $6.25M | 0.03% |
+8,541
| New | +$5.44M |
|
520
GE HealthCare
GEHC
$31.7B
| $6.24M | 0.03% |
84,276
+30,092
| +56% | +$2.09M |
|
521
Fulcrum Therapeutics
FULC
$290M
| $6.18M | 0.03% |
897,617
| – | – |
|
522
Kinder Morgan
KMI
$69.9B
| $6.15M | 0.03% |
209,118
+45,800
| +28% | +$1.26M |
|
|
UPB
523
Upstream Bio Inc
UPB
$370M
| $6.13M | 0.03% |
558,252
+1,189
| +0.2% | +$11K |
|
524
RingCentral
RNG
$5.09B
| $6.11M | 0.03% |
215,496
+56,022
| +35% | +$1.45M |
|
525
Truist Financial
TFC
$64.3B
| $6.09M | 0.03% |
141,651
+30,474
| +27% | +$1.19M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.